| 全年財務摘要 | | | | | --- | --- | --- | --- | | | 二零二五 | 二零二四 | | | | 財政年度 | 財政年度 | 變 動 | | 港 （百 萬 元） 收 入 | 2,740 | 1,983 | +38.2% | | （百 萬 港 元） 毛 利 | 809 | 824 | -1.8% | | 母公司權益持有人應佔虧損 | | | | | （百 萬 港 元） | (922) | (754) | +22.3% | | （港 仙） 每股虧損 | | | | | — 基本及攤薄 | (6.51) | (5.52) | +17.9% | | | 於 | 於 | | | | 二零二五年 | 二零二四年 | | | | 三月三十一日 | 三月三十一日 | | | （百 萬 港 元） 資產淨值 | 6,780 | 8,119 | -16.5% | | （港 每股資產淨值 元） | 0.48 | 0.53 | -9.4% | | 資產負債比率 | 58.7% | 62.9% | -4.2個百分點 | * 僅供識別 – 1 – 業 績 Wang On Group Limited（宏 ...

有关目标业务的业务合作涉及活动及业务营运，包括位于香港的任何物业(主要用作学生宿舍)的收购、 持有、融资、开发、重建、重新定位、翻新、租赁、出售或品牌推广。 继"日新舍"项目成功合作后，宏安集团、宏安地产集团与AG伙伴已同意开拓学生宿舍项目的进一步共 同投资机遇。是次合作将使订约方善用宏安地产于物业投资及管理方面的专长，以及AG伙伴作为投资 物业投资者的经验，从而促使宏安及宏安地产扩充业务组合。因此，订约方同意根据框架协议透过成立 新合营企业开展业务合作。 智通财经APP讯，宏安地产(01243)及宏安集团(01222)联合公布，于2025年6月12日，宏安地产的两间间 接全资附属公司Wickert Investments及Ever Sonic Enterprises分别与ADPF Holding及ADPF Investment订立 该等协议，内容有关出售 Fortune Harbour 及 Mega Hope 两家合营企业的 20% 权益及相关贷款，代价分 别为约8644万港元、80万港元，合计约8724万港元。 于完成后，Fortune Harbour及 Mega Hope的已发行股份将分别由Wicker ...

今天沪指险守3400点，咱们其实能很明显的感觉到最近有大金融在护盘，每天早盘热点板块都能看到银行、券商、保险的身影。但市场观望情绪依然浓 厚，量能还是跟不上。 资金在热点板块间的轮动更为频繁，板块分化加剧，最近比较火的，什么创新药、cpo、ip经济、贵金属、稀土永磁、汽车零部件等统统轮了个遍。市场 缺乏核心主线，资金难以形成一个稳定的合力。 后面咱们还是继续等待消息催化和新的市场驱动力。 下面来说几个比较重要的消息： 今天下午，港股蚂蚁集团概念股大幅拉拉升，云锋金融盘中一度飙涨100%，收盘涨约60%，耀才证券涨超10%。消息面上，蚂蚁集团旗下国际业务部门计 划在新加坡和香港申请稳定币相关牌照。最近稳定币概念一直被资金来回炒作，这个消息或影响明天A股相关板块。 虽然创新药迎来结构性的机会，但并非每家创新药公司都值得买，如果粉丝依然对这个板块感兴趣，咱们约一期，来仔细拆解下创新药产业的细分领域， 想看的评论区扣1。 今天午后，A股黄金股忽然震荡拉升，恒邦股份、潮宏基双双涨停，港股老铺黄金午后一度拉升涨超7%，年初至今已涨逾290%。消息面上中东地缘紧张 局势的急剧升温，显著提升了黄金的避险需求。 而就在黄金继续 ...

Revenue Performance - Revenue from Western medicine and health food products increased by approximately 5.8% to about HK$38,500,000 for the six months ended September 30, 2023, compared to HK$36,400,000 in the same period last year[2]. - The Group's revenue for the six months ended 30 September 2024 increased by approximately 8.3% to approximately HK$1,230.0 million, compared to approximately HK$1,136.1 million for the same period in 2023[199]. - The property development and trading segment recorded revenue of approximately HK$529.6 million and profit of approximately HK$57.2 million during the period, compared to approximately HK$375.1 million and HK$10.1 million respectively for the six months ended 30 September 2023[192]. - The WOP Group contributed approximately HK$427.9 million in revenue, primarily due to the delivery of the residential project "Larchwood," which accounted for approximately HK$258.4 million[192]. - The CAP Group recorded revenue of approximately HK$101.7 million, a slight decrease from approximately HK$116.7 million for the same period in 2023, attributed to lower property sales volume[194]. - The butchery business generated revenue of approximately HK$40.5 million for the period, compared to approximately HK$35.1 million for the six months ended September 30, 2023, indicating stable revenue growth[113]. Financial Position - As of September 30, 2024, the total debt of the Group amounted to approximately HK$5,310.8 million, down from approximately HK$6,346.9 million as of March 31, 2024[18]. - The net debt to equity ratio was approximately 52.4% as of September 30, 2024, compared to approximately 62.9% as of March 31, 2024[21]. - The Group's total interest-bearing debts amounted to approximately HK$5,310.8 million as of September 30, 2024, down from approximately HK$6,346.9 million on March 31, 2024[56]. - Cash resources amounted to approximately HK$1,082.2 million, down from approximately HK$1,333.1 million as of March 31, 2024[188]. - Total borrowings were approximately HK$5,310.8 million, resulting in a net debt of approximately HK$4,292.4 million as of September 30, 2024[188]. Equity and Commitments - As of September 30, 2024, the equity attributable to the parent company increased by approximately 1.8% to about HK$5,359.4 million, compared to approximately HK$5,266.3 million on March 31, 2024[40]. - The Group's total equity, including non-controlling interests, rose to approximately HK$8,197.6 million as of September 30, 2024, from approximately HK$8,119.0 million on March 31, 2024[40]. - The Group's capital commitments as of September 30, 2024, amounted to approximately HK$1,351.0 million, down from approximately HK$1,798.1 million as of March 31, 2024[23]. - The Group's share of capital commitments to joint ventures was approximately HK$465.9 million as of September 30, 2024, compared to approximately HK$548.3 million as of March 31, 2024[25]. Business Operations - The flagship brand "Pei Fu Ren" has maintained its position as the top-selling cough syrup in Hong Kong for 14 consecutive years[2]. - The Group is actively pursuing various business opportunities to respond to market volatility[2]. - The property at No. 19 Luk Hop Street, Kowloon, has been redeveloped into student accommodation with an occupancy rate exceeding 99%[14]. - The Group plans to continue investing in a professional property management team and advanced technology to enhance its property management business[17]. - The Group operates 10 agricultural produce exchange markets across five provinces in China, providing a solid foundation for future development and expansion[115]. - The Group manages approximately 450 market stalls under the "Wang On" and "Daily Good Food" brands, covering over 138,000 square feet, enhancing customer satisfaction through improved shopping experiences[110]. Risk Management - The Group has implemented internal control and risk management policies to address potential risks, including economic conditions in Hong Kong and construction cost escalations[79]. - The Group's risk management review identified major risks including the availability of suitable land for development and competition in the fresh markets sector[95]. - The Group faces significant foreign exchange risk related to Renminbi (RMB), with all bank borrowings denominated in Hong Kong dollars or RMB[75]. - The Group does not currently have a foreign currency hedging policy, which may expose it to currency fluctuations[91]. Profitability - Profit attributable to owners of the parent decreased to approximately HK$85.8 million, down 22.8% from approximately HK$111.0 million for the six months ended September 30, 2023[174]. - Gross profit for the Period was approximately HK$427.9 million, with a gross profit margin of 34.8%, down from approximately HK$434.7 million and 38.3% in the previous year[159]. - Selling and distribution expenses increased to approximately HK$232.1 million, up 17.6% from approximately HK$197.3 million for the same period in 2023[177]. - Fair value losses on financial assets and liabilities at fair value through profit or loss were approximately HK$22.2 million, an increase from approximately HK$10.6 million for the six months ended September 30, 2023[183]. Employee and Operational Changes - As of 30 September 2024, the Group had 2,005 employees, a decrease from 2,111 employees as of 31 March 2024, with approximately 46% located in Hong Kong and Macau[74]. - The Group completed a transaction on 5 September 2024, selling 100% equity interests in a target company for an initial consideration of approximately RMB28.9 million (approximately HK$31.9 million), with a final consideration of approximately RMB66.4 million[194]. - The Group and CAP recorded a gain on the disposal of approximately HK$35.8 million from the aforementioned transaction[194].

Financial Performance - Revenue for the six months ended September 30, 2024, was HKD 1,230 million, an increase of 8.3% compared to HKD 1,136 million in the same period of 2023[3] - Gross profit decreased by 1.6% to HKD 428 million from HKD 435 million year-on-year[3] - Profit attributable to equity holders of the parent company was HKD 86 million, down 22.5% from HKD 111 million in the previous year[3] - Basic and diluted earnings per share decreased by 24.7% to HKD 0.61 from HKD 0.81[3] - Total income from customer contracts was HKD 1,029 million, up from HKD 918 million, reflecting a strong growth in customer engagement[6] - The company reported a pre-tax profit of HKD 117 million, down from HKD 208 million in the previous year[6] - Other income totaled HKD 42,764,000, down from HKD 71,497,000, indicating a decrease of 40.3%[50] - The company reported a pre-tax profit of HKD 117,073,000, down from HKD 208,410,000, a decrease of 43.9%[36] - The total other income and net gain was HKD 78,901,000, compared to HKD 94,152,000 in the previous year, a decline of 16.2%[50] Assets and Liabilities - Net asset value increased by 1.0% to HKD 8,198 million from HKD 8,119 million[3] - The asset-to-liability ratio improved by 10.5 percentage points to 52.4% from 62.9%[3] - The total non-current assets amounted to HKD 9,119 million, showing a slight increase from HKD 9,060 million[20] - As of September 30, 2024, total current liabilities amounted to HKD 4,936,887, a decrease from HKD 5,993,498 as of March 31, 2024, representing a reduction of approximately 17.7%[22] - The net current assets were reported at HKD 2,075,426, down from HKD 2,528,894, indicating a decline of about 17.9%[22] - Total non-current liabilities decreased to HKD 2,997,541 from HKD 3,470,137, reflecting a reduction of approximately 13.6%[22] - The total equity increased to HKD 8,197,604 from HKD 8,119,010, showing a growth of about 1.0%[22] - The issued share capital decreased to HKD 141,667 from HKD 153,538, a decline of approximately 7.7%[22] - The group's total assets amounted to approximately HKD 16,132,000,000 as of September 30, 2024, down from HKD 17,582,600,000 on March 31, 2024[123] Revenue Breakdown - Revenue from property sales reached HKD 529,585,000, up from HKD 375,110,000, marking a 41.0% increase year-over-year[34] - Revenue from agricultural product trading commissions was HKD 42,253,000, compared to HKD 45,136,000, reflecting a decrease of 6.5%[34] - Revenue from property development and sales reached approximately HKD 529,600,000, with a profit of about HKD 57,200,000, compared to HKD 375,100,000 and HKD 10,100,000 respectively for the same period last year[89] - Revenue from property development and sales in China was approximately HKD 101,700,000, a slight decrease from HKD 116,700,000 in the same period last year[92] - The pharmaceutical and health food product segment reported revenue of approximately HKD 344,100,000, a decrease of about 6.0% from HKD 365,900,000 in the previous six months[104] Expenses and Costs - Selling and distribution expenses increased to approximately HKD 232,100,000 from HKD 197,300,000 year-on-year, primarily due to higher commission expenses and increased advertising costs[83] - Administrative expenses for the period were approximately HKD 254,700,000, slightly up from HKD 253,400,000 in the previous year[85] - The cost of property sales for the same period was HKD 433,485, significantly higher than HKD 302,892 in 2023[56] - Financing costs for the six months ended September 30, 2024, totaled HKD 172,814, a slight decrease from HKD 173,426 in the same period of 2023[53] Corporate Governance and Compliance - The company has adopted revised Hong Kong Financial Reporting Standards, which did not impact its financial position or performance significantly[28] - The company has complied with the corporate governance code, with the exception of the separation of roles between the chairman and CEO, which is currently held by the same individual[151] - The board emphasizes high levels of corporate governance, focusing on transparency, accountability, and independence to enhance competitiveness and operational efficiency[151] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited consolidated financial information for the six months ending September 30, 2024[154] Strategic Initiatives and Future Outlook - The group aims to increase land reserves through various channels, including public tenders and old building acquisitions[97] - The group is strategically positioning itself to leverage opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area, focusing on traditional Chinese medicine and health food sectors[146] - The group plans to launch four innovative health products targeting glucose levels, cholesterol levels, liver health, and joint function in the coming year, expected to positively contribute to its performance[146] - The group is actively expanding its cross-border e-commerce channels, achieving over 200% growth in sales compared to the same period last year[105] Employment and Economic Environment - As of September 30, 2024, the group employed 2,005 staff, a decrease from 2,111 on March 31, 2024, with approximately 46% based in Hong Kong and Macau[139] - The Hong Kong economy is expected to face challenges, with a projected GDP growth of about 3.3% year-on-year for Q2 2024, slowing to approximately 1.8% in Q3 2024 due to global uncertainties[143]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 - 1 - | --- | --- | --- | --- | |--------------------------------------------------------|-------|-----------------------|---------------------| | | 附註 | 二零二四年 \n 千港元 | 二零二三年 千港元 | | 收入 | | | | | 來自客戶合約之收入 | 4 | 1,539,203 | 3,165,341 | | 財資業務之利息收入 | 4 | 55,435 | 81,039 | | 其他來源之收入 | 4 | 388,596 | 357,078 | | 總收入 | | 1,983,234 | 3,603,458 | | | | | | | 銷售成本 | | (1,159,593) | (2,543,843) | | 毛利 | | 823,641 ...

Financial Performance - The Group's revenue for the six months ended 30 September 2023 decreased by approximately 44.6% to approximately HK$1,136.1 million, compared to approximately HK$2,050.5 million for the same period in 2022[14]. - Profit attributable to owners of the parent for the Period was approximately HK$111.0 million, a significant recovery from a loss of approximately HK$23.6 million in the same period last year[16]. - The decrease in revenue was primarily due to reduced sales from property development projects in which the Group has a controlling stake[15]. - The increase in profit was attributed to higher share of results from joint ventures and increased sales and gross profit from pharmaceutical and health food products[16]. - The Group did not recommend the payment of any interim dividend for the six months ended 30 September 2023, consistent with the previous year[13]. Cost and Expenses - The increase in finance costs was noted due to interest rate increments during the Period compared to the corresponding period in 2022[16]. - Administrative expenses were approximately HK$253.4 million, down from HK$270.5 million in the previous period, while selling and distribution expenses decreased to approximately HK$197.3 million from HK$203.6 million[23]. - Finance costs increased to approximately HK$173.4 million from HK$130.9 million, mainly due to rising interest rates[24]. Strategic Focus - The Group's performance reflects a strategic shift towards enhancing its pharmaceutical and health food product lines[16]. - The management highlighted the importance of addressing the challenges in property project deliveries to stabilize revenue streams moving forward[15]. - Future strategies may include further investments in joint ventures to leverage growth opportunities in the health sector[16]. - The Group aims to improve operational efficiency to mitigate the impact of rising finance costs on profitability[16]. Property Development - The property development segment recorded revenue of approximately HK$375.1 million and segment profit of approximately HK$10.1 million, down from HK$1,358.2 million and HK$130.0 million respectively for the six months ended 30 September 2022[39]. - Revenue from the Group's property development business in the PRC was approximately HK$116.7 million, a slight increase from HK$108.2 million in the previous period, attributed to more property sales deliveries[40]. - Revenue contribution from Wang On Properties Group's property development was approximately HK$258.4 million, primarily from sales of "The Met. Azure" and "LADDER Dundas" projects[43]. Agricultural and Fresh Market Operations - Fresh market and agricultural produce exchange market segment recorded a revenue increase of approximately 0.4% to approximately HK$332.7 million for the six months ended 30 September 2023[49]. - The CAP Group contributed approximately HK$193.8 million from agricultural produce exchange markets in China, while fresh market operations in Hong Kong contributed approximately HK$138.9 million[49]. - The Group operates 11 agricultural produce exchange markets across five provinces in China, significantly expanding its presence in this segment[57]. Pharmaceutical and Health Food Products - Revenue from the pharmaceutical and health food products segment reached approximately HK$365.4 million, representing a 22.3% increase from HK$298.7 million for the six months ended September 30, 2022[71]. - Revenue from Chinese pharmaceutical and health food products increased by approximately 23.8% to approximately HK$329.0 million, compared to HK$265.7 million for the six months ended September 30, 2022[72]. - New products, including Cordyceps Plus for respiratory support, were introduced to address seasonal influenza and long Covid symptoms[78]. Financial Position - The Group's net assets as of 30 September 2023 were approximately HK$9,250.5 million, a slight decrease from HK$9,379.4 million as of 31 March 2023[34]. - Total borrowings as of 30 September 2023 were approximately HK$6,536.3 million, resulting in a net debt position of approximately HK$5,351.4 million[34]. - The Group maintained a healthy cash balance of approximately HK$1,333.0 million as of 30 September 2023, down from HK$1,749.0 million as of 31 March 2023[34]. Investment and Acquisitions - On September 6, 2023, the Group agreed to acquire 2,007,700,062 ordinary shares of CAP for HK$200 million, increasing its equity interest in CAP from approximately 53.37% to 73.54%[149]. - The Group has partnered with APG Strategic Real Estate Pool for the acquisition and redevelopment of residential properties in Hong Kong[112]. - The Group's investment strategy remains prudent, with a focus on long-term holdings aimed at generating stable income[143]. Market Conditions and Economic Outlook - The Chief Executive's recent Policy Address included measures to ease property policies, such as reducing buyers' stamp duties on new homes by half, which is expected to positively impact the property market[169]. - The Group anticipates increased competition in fresh market operations due to a rise in the number of operators and the growing acceptance of online shopping and delivery services[170]. - The unemployment rate in Hong Kong dropped to 2.8% from July to September 2023, indicating an improving labor market[171]. Corporate Governance and Shareholding - As of September 30, 2023, Mr. Tang holds a total of 486,915,306 shares through Caister Limited and 531,000,000 shares through Billion Trader Investments Limited, both of which are wholly-owned by him[189]. - Ms. Yau holds 810,322,940 shares of WYT, which is about 69.19% of the total issued shares[191]. - The company has not granted any rights to acquire shares or debentures to any directors or chief executives during the period[197].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表聲明，並明確表示，概不對因本公佈全部或任何部分 內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 WANG ON GROUP LIMITED （宏 安 集 團 有 限 公 司 ） * （於百慕達註冊成立之有限公司） （股份代號：1222） 截至二零二三年九月三十日止六個月之 中期業績公佈 中期財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 變動 （未經審核） （未經審核） 百萬港元 百萬港元 收入 1,136 2,050 -44.6% 毛利 435 532 -18.2% 母公司權益持有人應佔溢利╱ （虧損） 111 (24) +562.5% ...

Lending Business Performance - The lending business generated revenue of approximately HK$43.1 million, a decrease of approximately 30.4% from HK$61.9 million in 2022, primarily due to a drop in the loan portfolio[1]. - As of March 31, 2023, the gross loan balance was approximately HK$277.8 million, down from approximately HK$461.3 million in 2022, reflecting a significant reduction in active loan accounts from 51 to 44[1]. - Secured loans accounted for approximately 81.8% of the loan portfolio, while unsecured loans made up approximately 18.2%[1]. - The top 5 customers represented approximately 48.8% of the loan portfolio, a decrease from 53.9% in 2022[1]. - The weighted average interest rate for secured loans was approximately 12.8% per annum, slightly down from 12.9% in 2022, while unsecured loans saw a more significant drop to approximately 13.3% from 16.2%[1]. - The loan-to-value ratio for secured loans was approximately 66.7%, down from 70.3% in 2022, indicating a cautious lending approach[1]. - Impairment losses for the year were approximately HK$2.2 million, a significant decrease from approximately HK$34.3 million in 2022, primarily due to expected credit loss allowances[1]. Asset Management and Revenue - The asset management services generated fee income of approximately HK$17 million, down from approximately HK$30.8 million in 2022, mainly due to a reduction in acquisition fees[3]. - Total revenue for the year ended March 31, 2023, was HK$3,603.5 million, representing a 94.1% increase from HK$1,856.0 million in 2022[53]. - Profit attributable to owners of the parent was HK$12.8 million, a significant recovery from a loss of HK$305.2 million in the previous year[53]. - Basic earnings per share improved to HK$0.09, compared to a loss of HK$2.06 per share in 2022[53]. Financial Position and Assets - Total assets decreased by 8.3% to HK$18.39 billion from HK$20.06 billion in 2022[38]. - Net assets declined by 2.3% to HK$9.38 billion, down from HK$9.60 billion in 2022[38]. - The gearing ratio improved to 49.4%, a decrease of 6.5 percentage points from 55.9% in 2022[38]. - Capital commitments as of March 31, 2023, amounted to approximately HK$1,409.3 million, down from HK$2,412.2 million in 2022[45]. - The Group's share of joint ventures' capital commitments increased to approximately HK$110.9 million from HK$43.3 million in 2022[45]. Dividends and Guarantees - Total dividends declared per share decreased to HK$0.04, a reduction of 60.0% from HK$0.10 in 2022[53]. - The Group provided guarantees for loans amounting to approximately HK$36.1 million to customers, down from HK$45.5 million in 2022[46]. Cash and Liquidity - The total liquidity investments and cash and bank balances as of March 31, 2023, were approximately HK$2,274.3 million, a decrease of approximately 6.4% from HK$2,429.9 million in 2022[9]. - Approximately 47.6% of liquidity investments were in debt securities, 19.4% in equity securities, and 33.0% in funds and other investments[9]. - Total cash and bank balances increased to approximately HK$1,616.3 million from approximately HK$1,489.9 million in 2022[67]. - The Group's cash and short-term realizable investments amounted to approximately HK$1,749.0 million, with cash and bank balances at approximately HK$1,616.3 million[111]. Operational Developments - The group has formed a new joint venture with Angelo, Gordon & Co., L.P. for the acquisition and operation of a property in Kowloon, Hong Kong, which includes a hotel with a gross floor area of approximately 285,000 square feet[61]. - The Group is leveraging its expertise in asset management to secure additional recurring income and explore strategic expansion opportunities[63]. - The Group is actively expanding its e-commerce channels, including its own online platform and selected third-party platforms[76]. - The Group has partnered with several developers and investment institutions for property development projects, with total investments exceeding HK$15 billion[96]. Cost and Expenses - The Group recorded administrative expenses of approximately HK$513.0 million for the year, a slight increase from HK$497.0 million in 2022[150]. - Selling and distribution expenses rose to approximately HK$452.9 million, up from HK$274.6 million in 2022, primarily due to increased property sales support services[150]. - Finance costs increased to approximately HK$288.4 million, compared to HK$207.6 million in 2022, attributed to rising interest rates[150]. - The average borrowing rate for the Group was 5.6%, up from 3.8% in 2022[150]. Product Development and Market Expansion - The company launched new products across five major categories of Chinese medicine, enhancing product diversity[123]. - The Group is planning to expand its retail network in Hong Kong, Mainland China, and Macau, considering both self-operated and franchised stores[165]. - The Group is developing new products, including cordyceps capsules and muscle relief oil, to enhance its product lineup[165]. - The Group's fresh market operations are adapting to challenges from online shopping and home delivery services by improving the shopping experience and exploring new business opportunities[163]. Agricultural and Cold Chain Development - The comprehensive cold chain circulation rate of fresh agricultural produce in Mainland China is only 19%, indicating significant potential for development in the cold storage industry[120]. - The Group plans to increase the development and construction of cold chains, cold storage, and logistics warehouses in existing market cities and the Greater Bay Area[120]. - The Group's subsidiary manages 11 agricultural produce exchange markets in densely populated areas and transportation hubs across Mainland China, enhancing its supply chain capabilities[117]. - The intelligent automatic packaging system developed by WYT can increase packaging efficiency six-fold and reduce material waste[102]. Urban Redevelopment and Market Presence - The company is focused on expanding its land reserves through public tenders and old building acquisitions to support future development projects[185]. - The total attributable gross floor area for ongoing urban redevelopment projects is approximately 65,000 square feet, with over 90% ownership secured[183]. - The company is actively pursuing urban redevelopment projects, holding over 90% ownership in these projects, with a total gross floor area of approximately 65,000 square feet planned for redevelopment[185]. - The Group managed a portfolio of around 600 stalls in the fresh market segment, covering over 150,000 square feet, and aims to enhance customer experience through improved shopping environments[191]. - The company plans to identify high population density areas for establishing new fresh markets and mini fresh markets to expand its market presence[191].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 WANG ON GROUP LIMITED （宏 安 集 團 有 限 公 司）* （於百慕達註冊成立之有限公司） （股份代號：1222） 截至二零二三年三月三十一日止年度 全年業績公佈 全年財務摘要 二零二三 二零二二 財政年度 財政年度 變動 收入（百萬港元） 3,603 1,856 +94.1% 毛利（百萬港元） 1,060 806 +31.5% 母公司持有人應佔溢利╱（虧損） 淨額（百萬港元） 13 (305) 不適用 每股盈利╱（虧損（）港仙） – 基本及攤薄 0.09 (2.06) 不適用 每股股息（港仙） ...